| 1. |
- Elad, Sharon, et al.
(författare)
-
Topical immunomodulators for management of oral mucosal conditions, a systematic review; part I: calcineurin inhibitors.
- 2010
-
Ingår i: Expert opinion on emerging drugs. - : Informa Healthcare. - 1744-7623 .- 1472-8214. ; 15:4, s. 713-26
-
Tidskriftsartikel (refereegranskat)abstract
- Topical immunomodulators have been used for the management of oral mucosal diseases. Topical immunomodulating preparations may have utility in local management of oral disease which is resistant to topical steroids and oral findings of an immunologic-mediated systemic disease with primary or persisting, oral mucosal involvement.
|
|
| 2. |
- Elad, Sharon, et al.
(författare)
-
Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents.
- 2011
-
Ingår i: Expert opinion on emerging drugs. - : Informa Healthcare. - 1744-7623 .- 1472-8214. ; 16:1, s. 183-202
-
Tidskriftsartikel (refereegranskat)abstract
- INTRODUCTION: Topical immunomodulating preparations have utility in inflammatory/immune-mediated oral mucosal disease resistant to topical steroids, in immunologically mediated systemic disease with primary oral involvement or more severe lesions primarily involving the oral mucosa. AREAS COVERED: This paper is the second part of a systematic review of a variety of topical immunomodulators for management of immune/inflammatory oral mucosal conditions. The literature search revealed studies of azathioprine, benzydamine, GM-CSF and G-CSF, tetracyclines, retinoids, imiquimod, amlexanox, sirolimus and bacillus Calmette-Guerin polysaccharide nucleic acid. Weighted conclusions are provided for the topical use of each of the immunomodulators reviewed in the management of these oral diseases. EXPERT OPINION: Topical immunomodulators may be useful as second line treatment in several oral diseases, particularly oral lichen planus and recurrent aphthous stomatitis. Benzydamine was found to be preventive in radiotherapy-induced mucositis; however, it is unclear if this outcome is related to its immunomodulating effects or other mechanisms of action. Topical application of tetracyclines and retinoic acid also shows potential anti-inflammatory actions.
|
|
| 3. |
- Singer, Susanne, et al.
(författare)
-
International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV.
- 2019
-
Ingår i: Head & neck. - : Wiley. - 1097-0347 .- 1043-3074. ; 41:6, s. 1725-1737
-
Tidskriftsartikel (refereegranskat)abstract
- We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43).We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test-retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons.Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales.Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.
|
|
